投资者日：TIDES势头延续，早期研发初现回暖

药明康德(603259)
    药明康德举办了投资者日活动，我们认为此次会议的要点如下：1）TIDES业务发展势头不变，产能扩张迅速、管线储备丰富；2）早期研发显现进一步复苏的信号，将拉动占公司总收入约1/3的早期业务收入的增长；3）精细化运营助力公司在面对宏观不确定性以及进行全球产能扩张的同时保持有韧性的盈利能力。
    产能扩张支持TIDES业务保持发展势头。公司将按计划在25年底将多肽产能扩张至超过10万L，显著高于2024年底的4.1万L。截至25年8月，药明康德TDIES管线包含23个GLP-1类项目，其中16个在临床2/3期，占全球的26%。除了GLP-1类项目，管线内的其他分子例如环肽和核酸项目也已进入商业化或者PPQ阶段，将为TIDES业务带来业绩增量。此外，TIDES业务完美体现了公司“跟随分子”战略，在1H25，TIDES管线中有19个项目从R阶段推进至D阶段，占TIDES业务D阶段1H25新增新分子数的50%。管理层维持TIDES收入全年增长超过80%的指引。管理层目标未来TIDES业务的全球市占率高于传统小分子业务(D阶段~16%市占率)。
    早期研发需求复苏信号进一步显现。国内外早期研发需求均看到积极催化因素。在国内市场，创新药BD热潮以及其引发的资本市场融资复苏，为中国biotech创新研发带来了资金支持。在海外市场，美联储在9月份再次开启降息通道，有望刺激海外biotech融资的复苏。作为全球药物早期研发最大的赋能平台之一，药明康德将会显著受益于全球早期研发需求的复苏。1H25，公司的临床前新签订单同比增长14.5%，其中来自美国客户的新签订单同比增长19.9%。新分子的研发客户需求维持强劲增长，1H25PDC相关DMPK收入同比增长25%，CGT相关生物分析收入增长393%。
    精细化运营提升。公司的CRDMO商业模式以及前瞻的产能建设带来了充足的订单，公司强大的执行能力也保证了订单的交付效率以及利润率。公司的新厂房从投产至满负荷运转所需的时间已从2017年的22.6个月大幅度缩短至2024年的2.4个月。公司开发的智能排产系统将产能空置率大幅度降低，API设备的使用率从2020年的60%提升至1H25的72%。小分子和多肽生产的自动化率达到90%/80%，降低人工成本的同时显著提高了操作的准确性。精细化运营助力公司在面对宏观不确定性以及进行全球产能扩张的同时保持优秀的盈利水平。1H25公司的经调整毛利率和净利润率达到44.5%和30.4%，均为公司历史最高。管理层有信心保持有韧性的盈利能力。
    维持买入评级。小幅上调药明康德目标价至118.79元人民币（WACC：9.39%，永续增长率：2.0%），以反映全球早期研发需求改善的积极信号。我们预计公司在2025E/26E/27E持续经营收入同比增长16.0%/15.9%/15.8%，经调整non-IFRS净利润同比增长16.2%/17.6%/16.4%。

上半年业绩稳健；维持“买入”评级

豪威集团(603501)
    豪威集团公布2025年上半年业绩。公司上半年收入同比增长15%至140亿元人民币，主要受模拟解决方案（同比+21%）与分销业务（同比+42%）的双位数增长驱动。毛利率基本稳定在30.5%（同比提升1.3个百分点）。净利润同比大幅增长48%至20亿元人民币。受经营杠杆效应和成本管控影响，净利率提升至14.5%（去年同期为11.3%）。公司核心业务CIS（图像传感器）销售额创103亿元人民币的新高（同比增长11%），其中汽车、安防、新兴物联网及医疗CIS分别增长30%、17%、249%和68%，抵消了手机CIS的疲软（同比下滑19%）。我们认为公司在CIS市场占据有利地位，尤其是在汽车和医疗CIS等市场均保持份额领先。预计2025/26财年收入将同比增长18%、25%，净利润增长24%、50%。维持"买入"评级，目标价为173元人民币。
    汽车CIS仍是公司增长的主要驱动力。汽车CIS收入为38亿元人民币，同比增长30%，占CIS板块收入的37%。该业务增长主要受到ADAS渗透率提升与座舱影像需求强劲的驱动。凭借约30%的全球市场份额（TechInsights）以及中国“智驾平权”政策的推动，我们预计公司2025/26年的汽车CIS销售额有望实现40%的同比增长。
    手机CIS上半年承压（收入同比下滑19%）。这主要由于产品需求周期的转换（OV50H产品生命周期进入尾声，导致需求有所下降），以及中国智能手机市场复苏缓慢（在补贴政策的推动下，国内手机一季度出货量同比增长3.3%；但二季度需求有所下滑，出货量同、环比下降4%、4%）。我们认为下半年智能手机市场需求将因季节性有所增长，但预计豪威的手机CIS全年收入会出现同比下降，约15%（IDC/Counterpoint预测2025年智能手机出货量仅增长0.6%/1.9%）。随着2亿像素传感器的客户渗透及新产品的逐步出货，2026年该业务收入将有望恢复增长。
    新兴物联网与医疗CIS呈现爆发式增长，安防市场需求逐步复苏。受益于运动相机、XR、机器视觉需求的提振，上半年新兴物联网CIS收入同比大幅增长249%至12亿元人民币。医疗CIS同比增长68%至4.43亿元人民币。安防CIS同比增长17%至8.27亿元人民币，得益于高端产品（Nyxel技术）逐步被客户接受以及市场需求有所复苏。我们预计2025年新兴物联网CIS与医疗CIS将分别保持230%、50%的高速增长。
    维持"买入"评级，目标价为173元人民币，基于33.6倍2026年市盈率（与两年历史平均一致）。原目标价为176元，基于41倍2025年市盈率。因手机CIS增长放缓、毛利率承压（分销占比提升，导致产品结构发生变化），我们将公司2025/26年净利润预测分别下调19%、15%。我们对公司明年的发展仍持乐观展望，考虑到明年手机CIS新品的逐步上量以及利润率的改善（2026年50%的净利润增速）。主要风险：智能手机出货疲软以及市场竞争加剧。

二季度业绩强劲：销售创新高，利润率扩张；维持“买入”评级

深南电路(002916)
    深南电路发布了强劲的2025年二季度业绩。公司收入增速提升，同时利润率改善，尤其是核心PCB业务表现亮眼。二季度收入为57亿元人民币，创历史新高，同、环比增长30%、19%，超出彭博一致预期6%。净利润为8.69亿元，同、环比增43%、77%，超出彭博一致预期41%。毛利率环比提升2.8个百分点至27.6%，净利率创下15.5%的历史新高（去年同期、上季度分别为13.9%、10.3%）。鉴于公司在AI服务器、数据中心及汽车电子等高增长领域的战略布局，维持“买入”评级。公司的泰国产线、南通四期项目及现有工厂技改带来产能的持续扩张，叠加研发投入稳定在销售额的6%-7%，这将持续巩固公司的竞争优势，并支撑其长期增长。目标价上调至235元人民币。
    印制电路板业务：作为公司的核心增长驱动力，业务板块利润率持续扩张。上半年印制电路板业务营收（占总销售额60%）创63亿元新高，同比增长29%，较去年下半年增长11%。该增长主要受无线通信基础设施、数据中心及汽车应用强劲需求推动，三者收入合计已达到75%。受益于产品结构优化、产能利用率提升的拉动，印制电路板业务的毛利率从2024财年的31.6%显著上升至上半年34.4%。我们预计公司2025年印制电路板业务的收入将同比增长35%至141亿元，毛利率维持在34.4%，较上半年持平。
    封装基板：存储需求强劲推动销售额创新高，产能爬坡致利润率承压。受存储产品需求回暖驱动，上半年封装基板业务的销售额为17亿元（占总收入的17%），同比增长9%、较去年下半年增长10%。因广州新工厂产能爬坡以及原材料成本上升的影响，板块毛利率同比下降10.3个百分点至15.1%。管理层表示该业务亏损较2024年下半年有所收窄，上半年毛利率已环比改善4.4个百分点，呈现逐步复苏趋势。我们预计公司2025年封装基板销售额将达到37亿元，毛利率回升至17%。
    维持"买入"评级，目标价上调至235元，基于33.7倍2026年预测市盈率，较五年历史均值高出约1个标准差，反映行业上行周期动能（此前为31倍，与5年历史均值持平）。考虑到需求超预期增长以及利润率扩张，我们将公司2025/26年收入预测上调5%/11%，净利润预测上调25%/15%。潜在风险包括：1)下游市场需求复苏不及预期；2)产能瓶颈；3)上游原材料价格波动。

长期增长轨迹稳健，无惧季节性波动影响；维持“买入”评级

北方华创(002371)
    北方华创发布了稳健的2025年二季度业绩，公司收入为79亿元人民币，同比增长22%，环比下降3%，主要因一季度收入为高基数（历史第二高）所导致的季节性波动。毛利率收窄至41.3%（同比下降6.0个百分点、环比下降1.7个百分点），受电子元器件业务利润率较低的影响所致。净利润为16亿元（同比下降2%、环比增长3%）。净利率提升至20.5%（2024年、25年一季度分别为18.8%、19.3%），显示公司出色的运营与成本管控能力。我们持续看好公司的成长轨迹，公司在中国半导体设备国产替代进程中占据重要的战略地位。我们预计2025/26年收入将同比增长32%/26%。重申"买入"评级，目标价上调至460元人民币。
    中国半导体设备龙头正受益于国产替代的趋势。我们认为北方华创半导体设备业务的增长势头稳健，上半年收入超130亿元（2024年全年营收超210亿元，预计公司在国内市占率超5%）。按产品类别划分，公司上半年的刻蚀、沉积、热处理以及清洗设备收入分别超50亿元、65亿元、10亿元和5亿元。四大品类合计占销售额的80%以上（去年上半年约占70%）。我们预计公司上半年半导体设备的销售额同比增长约50%。
    公司通过研发与收购加速平台扩张，有效提升市场渗透与盈利能力。公司自2025年3月进军离子注入设备市场，并推出多款12英寸产品。同时，公司已完成对芯源微（688037CH，未评级）的收购，新增涂胶显影、键合及清洗设备的能力（芯源微的清洗产品收入未计入公司上半年销售额）。截至2025年6月，公司持有芯源微17.87%股权，为第一大股东。我们认为北方华创的产品组合扩展有望提升公司的市场份额，同时收购带来的协同效应预计会提高公司的盈利能力。我们预测2025/26年公司的半导体设备销售额将同比增长47%/31%。
    维持“买入”评级，新目标价为460元人民币。目标价基于35倍2026年预测市盈率，较五年历史均值持平（此前为36.8倍2025年预测市盈率）。凭借丰富的产品组合和持续加速的国产替代趋势驱动，我们认为北方华创是中国半导体设备市场上的最具优势的参与者。主要风险包括：(1)国内资本开支不及预期；(2)地缘政治风险导致供应链中断；(3)市场竞争加剧。

Solid 1H25 results; Maintain BUY

豪威集团(603501)
    OmniVision reported 1H25 results. 1H revenue rose 15% YoY to RMB14.0bn,led by double-digit growth in Analog Solutions (+21% YoY) and Distribution(+42% YoY). During the period, gross margin remained stable at 30.5% (+1.3 pptsYoY), while net profit surged by 48% YoY to RMB2.0bn. NPM improved to 14.5%(from 11.3% in 1H24), reflecting operating leverage and cost control. The salesof OV’s core business, CIS, reached a record RMB10.3bn (+11% YoY), with auto,security, emerging IoT, and medical CIS growing 30%, 17%, 249%, and 68%YoY, respectively, offsetting weakness in mobile CIS (-19% YoY). We believeOmniVision is well-positioned in the CIS market, with leading market share in autoCIS, medical CIS, etc. We forecast its revenue to grow at 18%/25% YoY in2025/26E, while NP to increase by 24%/50% YoY. Maintain BUY with TP ofRMB173.
    Auto CIS remained a key growth pillar, accounting for 37% of segmentsales with revenue of RMB3.8bn (+30% YoY). The growth was fueled byADAS penetration and cabin imaging demand. With a ~30% global marketshare (per TechInsights) and tailwinds from China’s “intelligent drivingequality” policy, we expect OV’s auto CIS sales to grow at 40% YoY in both2025E and 2026E.
    Mobile CIS faced headwinds in 1H (-19% YoY) due to cyclical demandtransition (end-of-cycle demand for OV50H EOL) and slow smartphonerecovery in China (domestic shipment grew 3.3% YoY in 1Q25 ongovernment subsidies but decreased 4%/4% YoY/QoQ in 2Q as demand fell).We expect a seasonal pickup in 2H, but project full-year mobile CISrevenue to decline 15% YoY as the headwinds persist (2025 smartphoneshipment to grow by a merely 0.6%/1.9% YoY, per IDC/Counterpoint).Growth should resume in 2026E with design-wins in 200MP sensors andnew product cycles.
    Emerging IoT and Medical CIS showed explosive growth, while securitydemand gradually recovers. Emerging IoT revenue surged by 249% YoYto RMB1.2bn in 1H25, driven by sports cameras, XR, and machine vision.Medical CIS rose 68% YoY to RMB443mn. Security CIS grew by 17% YoY toRMB827mn, due to rising adoption of its high-end products (Nyxel tech) andmarket recovery. We expect Emerging IoT and Medical CIS to maintainsignificant growth at 230%/50% YoY in 2025E.
    Maintain BUY with TP of RMB173, based on 33.6x 2026E P/E (in-line withhistorical 2-year average). Previous TP was RMB176 (41x 2025E P/E). Wecut 2025/26E net profit forecasts by 19%/15% on slower mobile CIS rampand GPM headwinds from mix shift (greater distribution sales contribution).We remain optimistic on OV with 50% YoY profit growth projection for 2026E,considering new mobile CIS product ramp-up and margin improvement. Keyrisks: Soft smartphone shipments and intensified competition.

1H25 earnings saved by sub-brands; Maintain BUY

珀莱雅(603605)
    Proya delivered 1H25 revenue and attributable NP growth of +7.2% and +13.8%YoY respectively, missing BBG consensus by 3%/4% primarily driven bysustained momentum across sub-brands and continued pressure on core brandProya. GP margin improvement was partly offset by heavier selling expenseson 618 promotion and sub-brands marketing. The company announced HKlisting plan to accelerate overseas expansion. We trim our TP by 3% toRMB129.83 to reflect lower earnings forecast, based on 30x 2025E P/E,Maintain BUY.
    Sub-brands growth cushioned pressure of core brand. Rev. of corebrand Proya dropped 0.1% YoY in 1H25 on a high base and fiercercompetition. Sub-brands TIMAGE/OR/ INSBAHA sustained high growth withrevenue up 21/102/80% YoY, with their combined revenue contribution liftedto 20.2% in 1H25, up 4.7ppts YoY. Looking forward, management has laidout a clear plan to enrich the product matrices across sub-brands: TIMAGEwill iterate base-makeup technologies; OR will focus on anti-hair-losssolutions with aromatherapy concepts; and INSBAHA will deepen nichecolor cosmetics. International expansion is set to accelerate, with ORlaunches planned in Hong Kong and Japan and Hapsode rollout inSoutheast Asia. The proposed HK listing should also provide capital andbranding support to scale overseas and consolidate the company’s multibrand advantages.
    7M25 sales largely in line with the industry. In 1H25, offline sales dropped21.3% YoY while online sales grew steadily at 9.2% YoY (self-operated+4.2% / distribution +25.9%). Based on our tracked cosmetics database,Proya’s GMV (covered Proya/Timage/OR) on Taobao & Douyin combinedgrew 4% YoY in 7M25, slightly slower than industry’s 5%.
    Cost savings outcome partly offset by rising marketing expenses.Gross margin expanded by 3.6ppt YoY to 73.4% in 1H25 thanks to costcontrol efforts such us shifting freebies from “mini” to “mid-size” to reducepackaging & unit marketing costs. SG&A ratio rose by 2.6ppt YoY givenheavier 618 promotions cost and celebrity endorsements for sub-brands.With 2H marketing will likely remain elevated around 11.11 shopping festival,we expect the full-year selling expense ratio to trend higher.
    Maintain BUY. We maintain our BUY rating, with TP cut 3% to RMB 129.83,on 30x 2025E P/E. Risks: worse-than-expected consumption sentiment,intensifying competition, and raw material price hike etc.

收入和盈利创新高，利润率显著提升；维持“买入”评级

中际旭创(300308)
    中际旭创公布了强劲的2025年二季度业绩。在高性能光模块需求推动下，公司二季度收入达81亿元人民币，创历史新高，同、环比增长36%、22%。净利润大幅增长至24亿元，同、环比增长79%、52%，超出彭博一致预期28%。毛利率与净利率分别攀升至41.5%、29.7%，创历史新高，分别高于市场预期5.7个百分点和7.2个百分点。公司宣布每股0.4元的首次中期分红，提升股东回报。我们维持对公司的“买入”评级，目标价上调至415元人民币，对应30倍2026年预测市盈率（此前为27倍25年预测市盈率），同时上调盈利预测以反映对公司的乐观展望，基于AI驱动需求持续增长以及公司优秀的执行力。
    光模块的强劲销售推动收入提升（同、环比增长40%、98%）。管理层强调800G产品出货强劲，1.6T产品于二季度开始量产并将在下半年加速交付。值得注意的是，公司基于硅光子技术的1.6T解决方案已获得头部云厂商客户的认证。
    AI资本支出周期推动公司业绩持续增长。海外收入（占2025年上半年总收入的86%）仍是增长的核心驱动力。据彭博一致预期，四大云厂商（亚马逊、谷歌、Meta、微软）的2025、26年资本支出总额将同比增长53%、17%至3,300亿美元、3,500亿美元，较2025年5月的一致预期分别高出5.7%、5.6%。基于超预期的AI基础设施投资，我们将2025、26年公司收入预测分别上调5%、5%，预计公司2025年收入将同比增长60%、32%。
    800G、1.6T的放量及硅光子技术应用推动利润率显著扩张。上半年光模块毛利率同比提升6.1个百分点至40.0%，净利率同比上升5.8个百分点至29.7%。利润率创新高，主要由以下因素驱动：1）800G、1.6T等高毛利产品占比的提升；2）利润率更高的硅光子方案渗透率持续增加；3）高效的供应链管理（二季度原材料库存环比增17%）。以硅光子技术为主的1.6T产品利润率显著优于前代产品。我们将2025、26年毛利率预测从39%、38%上调至43.0%、42.7%。预计随着1.6T产品的规模出货以及硅光子方案的持续推广，公司利润率将进一步扩张。1.6T产品于下半年的大规模量产有望带动公司利润率环比持续改善。
    维持“买入”评级，目标价上调至415元人民币，基于30倍2026年预期市盈率，高出五年历史均值1个标准差，反映AI光模块市场的高速增长以及公司的领先市场地位。基于更高的收入与毛利率假设，我们将公司2025、26年的净利润预测上调28%、30%。主要风险包括：1）AI资本开支不及预期，2）地缘政治、关税的不确定性，以及3）供应链中断及市场竞争加剧等。

Record revenue and earnings coupled with significant margin expansion; Maintain BUY

中际旭创(300308)
    Innolight delivered exceptionally strong2Q25results.Quarterly revenuewas a record RMB8.1bn,up36%/22%YoY/QoQ,driven by robust demand forhigh-end optical modules.Net profit surged to RMB2.4bn,up79%/52%YoY/QoQ,beating BBG consensus by28%.Both GPM and NPM hit recordhighs at41.5%/29.7%,outperforming consensus by5.7ppt/7.2ppt.Innolightannounced its first interim dividend of RMB0.4per share,boosting shareholderreturns.Maintain BUY and raise TP to RMB415,based on30x rollover2026EP/E(previously27x2025E P/E),as we revise up earnings forecasts to reflectour positive outlook on the company,indicating sustained momentum in AI-driven demand and mgmt.’s superior execution.
    Sequential revenue improvement driven by optical transceivers’salesincrease(up40%/98%YoY/QoQ).Mgmt.highlighted strong shipments of800G products,with1.6T commencing ramp-up in2Q and shipment toaccelerate through2H25.Notably,the company’s silicon photonics(SiPh)based1.6T solutions are gaining traction with leading cloud customers.
    AI capex cycle to support sustained growth.Overseas revenue(86%of1H25sales)remained the primary growth driver.Per Bloomberg consensus,combined capex from key hyperscalers(Amazon/Google/Meta/Microsoft)isprojected to grow53%/17%YoY to US$329/350bn in2025/26E,revised upby5.7%/5.6%vs.consensus in May2025.We raise our2025/26E revenueforecasts by5%/5%,respectively,factoring in stronger-than-expected AIinfrastructure investments.We project2025E revenue to increase60%/32%YoY.
    Significant margin expansion due to robust800G/1.6T shipments andSiPh adoption.In1H,optical transceivers’GPM rose6.1ppt YoY to40.0%,while NPM increased by5.8ppt YoY to29.7%.The record margins weredriven by1)a higher sales contribution of800G/1.6T products,2)increasingadoption of higher-margin SiPh solutions,and3)efficient supply-chainmanagement(raw material inventory rose17%QoQ in2Q).1.6T products,predominantly shipped in SiPh form,yield a better margin than earliergenerations.We lift2025/26E GPM projections to43.0%/42.7%from39%/38%,anticipating further margin expansion as1.6T shipments scaleup and SiPh solutions increase.Mass production of1.6T products in2Hshould support sequential margin improvements.
    Maintain BUY,with TP adjusted to RMB415,based on30x rollover2026EP/E,equivalent to1-SD above5-year historical avg,justified by Innolight’sleadership in a fast-growing AI optical market.Our NP forecasts for2025/26E are revised up by28%/30%,on higher revenue and GPM
    geopolitical/tariff uncertainties,supply chain disruptions and intensifiedcompetitions,etc.

Margin headwinds persist from business model transition; Maintain HOLD

卓胜微(300782)
    Maxscend released2Q25results.Revenue was RMB948mn in2Q25,up25%QoQ from a low base in1Q but down13%YoY,reflecting continued softness inend-market demand and intensified competition.During the period,GPM fell to27%(-4ppt/-14ppt vs.1Q25/2Q24)in2Q25,missing BBG consensus estimatesof34%,due to1)ongoing price pressure,2)impact from depreciation,and3)lower-than-expected fab utilization.Net loss widened to RMB101mn in2Q(NLM:-11%)from-RMB47mn in1Q(NLM:-6%).We cut our2025/26E revenueforecasts by21%/22%to reflect weaker-than-expected demand and persistentpricing pressure.We also lower GPM projections by9ppts/7ppts to32%/37%in2025/26E,factoring in near-term margin headwinds from elevated depreciation.Maintain HOLD with TP of RMB81.5.
    Revenue declined on soft demand,while product developmentprogress stayed intact.China’s smartphone shipment grew3.3%YoY in1Q25on government subsidies but decreased4%/4%YoY/QoQ in2Q asdemand fell.The weak recovery in market demand(2025smartphoneshipment to grow by0.6%/1.9%YoY,per IDC/Counterpoint)and slower-than-expected industry consolidation weighed on Maxscend’s performance.1H25sales dropped25%YoY,although RF modules now accounted for44%of total revenue,up from36%/42%in FY23/24.This shift demonstrates thecompany’s progress in product development(i.e.,L-PAMiD,equipped within-house MAX-SAW,reflecting a fully localized supply chain).We expectmodule revenue to exceed50%of total sales in2027E,aligning with industrymodularization and localization trends.However,without a strong reboundin demand,we expect Maxscend’s overall revenue to decrease by9%in2025E.
    Margin headwinds persist.Maxscend booked a D&A expense ofRMB323mn in1H25,up22%YoY from RMB265mn in1H24.Althoughdepreciation growth may have peaked,absolute expense is expected toremain elevated in the near term as the company ramps up its12-inch IPDline(1H25capacity:5kwm).We think improved fab utilization across the6-inch and12-inch lines should help ease margin pressure over time.Weexpect overall GPM to be32%in2025,given ongoing margin erosion as fabramps up.
    Maintain HOLD.We see2025-26E as transitioning years for Maxscend.Ournew TP is based on45x2026E EV/EBITDA(vs.prior45x2026E P/E),slightly higher than0.5-SD below5-year historical avg.of44x,reflectingongoing business model shift toward fab-lite/IDM.While Maxscend is well-positioned in the RFFE market and China’s localization,we think its marginrecovery may take another year.Upside catalysts:stronger-than-expectedrecovery,accelerated localization.Potential downside risks:slower capacityramp-up,R&D delays.

Impressive growth amid uncertain environment

药明康德(603259)
    WuXi AppTec reported better-than-expected 1H25 results, with revenueincreasing by 20.6% YoY (including 24.2% YoY growth for continuing operations)and adj. non-IFRS net profit surging by 44.4% YoY. Revenue from continuingoperations and adj. non-IFRS net profit accounted for 47.5% and 54.4%,respectively, of our full-year forecasts, both higher than the historical ranges.WuXi AppTec delivered strong operational execution, despite ongoing macrouncertainties. As such, mgmt. raised its full-year guidance for 2025, expectingrevenue of continuing operations to grow by 13-17% (vs prior guidance of 10-15%) and adj. non-IFRS net profit margin to expand in 2025.
    Robust commercial demand drives CDMO outperformance. The robustdemand for late-stage clinical and commercial manufacturing has been a keygrowth driver for the global CXO industry in the post-COVID era. As a globalleader in the chemical drug CDMO sector, WuXi AppTec has substantiallybenefited from this trend. In 1H25, its TIDES revenue surged by 141.6% YoYthanks to faster-than-expected manufacturing capacity ramp-up. Mgmt raisedits full-year guidance for TIDEs revenue growth from 60% to 80%. Revenuefrom small molecule D&M grew by 17.5% YoY, marking a notable reboundfrom the negative growth seen in 2023/2024. In addition, the volatilities in USChina tariffs seemed to have limited impact to the Company’s first halfoperation, in our view. Despite ongoing volatility in the global macroenvironment, we believe that the sustained demand for commercial drugmanufacturing is likely to continue, supporting the growth of leading CDMOplayers like WuXi AppTec.
    Expanding global capacity to support long-term growth. As of end-1H25,WuXi AppTec’s backlog impressively grew by 37.2% YoY, with backlog ofTIDES increasing even more strongly at 48.8% YoY. The mgmt. reiteratedtheir plan to increase the Company’s peptide capacity to over 100k liters bythe end of 2025 to support the demand from both existing commercialprojects and growing pipelines. At the same time, capacity expansion effortsare underway at multiple sites, including Changzhou (China), Singapore, theUS and Switzerland. WuXi AppTec has reaffirmed its capex target of RMB7–8bn in 2025, and anticipated possible increases in capex in the coming years.
    Recovery in early-stage R&D still takes time. While revenue from earlystage R&D services showed sequential improvements in 1H25 over 2024,mgmt. viewed that a meaningful recovery in early-stage R&D demand willtake time. Early-stage R&D services contribute ~30% of the Company’s totalrevenue. The global biotech financing usually serves as an early indicator ofearly-stage R&D demand.
    Maintain BUY. We raise our DCF-based TP from RMB77.22 to RMB116.56(WACC: 9.42%, terminal growth: 2.00%; both unchanged), to factor in theupgraded guidance and the improved macro environment such as the USChina tariff. We now expect revenue from continuing operations to grow by16.0%/ 15.9%/ 15.8% YoY and adjusted non-IFRS net profit to grow by16.2%/ 17.6%/ 16.4% YoY in 2025E/ 26E/ 27E, respectively

2Q25 profit grew 19% YoY but largely on FX gains

浙江鼎力(603338)
    Zhejiang Dingli (Dingli) preannounced over the weekend the key financialfigures for 1H25. We calculate that revenue grew 1% YoY to RMB2.4bn in 2Q25,which we think is a resilient figure given the volatile tariff level during the quarter.Net profit in 2Q25 grew 19% YoY to RMB622mn, largely driven by FX gains(strong EUR and GBP) which made the results slightly better than ourexpectation. We slightly revise up our 2025E earnings forecast by 3% largely onhigher FX gains. Our TP is revised up from RMB44 to RMB48, to reflect theimproving progress on the Sino-US tariff talks. That said, we maintain ourcautious stance on Dingli as we think it will take time for the Company to adjustits strategy (i.e. high proportion of capacity in China serving the US market).Maintain HOLD.
    1H25 key financials. Revenue grew 12% YoY to RMB4.3bn. Net profit grew27% YoY to RMB1.05bn, which accounted for 55% of our new full-year netprofit forecast.
    Valuation. We revise up our TP from RMB44 to RMB48, based on 12.8x2025E P/E (up from 12x previously) which is derived from 0.5SD (1.0SDpreviously) below the three-year average P/E of 13.5x. Our narrowed targetdiscount is to reflect the improving progress on the Sino-US tariff talks.
    Upside risks: (1) Substantial reduction of proposed tariffs on China; (2)stronger-than-expected demand in other countries that offsets theweakness in the US.
    Downside risks: (1) Further increase in tariffs in the US; (2) furtherintensified competition in China’s AWP market; (3) weakness of overseasdemand.